Kristel Paque1,2, Robert Vander Stichele1, Monique Elseviers1,3, Koen Pardon2, Tinne Dilles3,4, Luc Deliens2,5, Thierry Christiaens1. 1. 1 Clinical Pharmacology Research Unit, Heymans Institute of Pharmacology, Ghent University, Ghent, Belgium. 2. 2 End-of-Life Care Research Group, Vrije Universiteit Brussel (VUB) & Ghent University, Brussels, Belgium. 3. 3 Faculty of Medicine and Health Sciences, Department of Nursing Science, Centre for Research and Innovation in Care (CRIC), University of Antwerp, Antwerp, Belgium. 4. 4 Department of Nursing and Midwifery, Thomas More University College, Lier, Belgium. 5. 5 Department of Medical Oncology, Ghent University Hospital, Ghent, Belgium.
Abstract
BACKGROUND: : Knowing the barriers/enablers to deprescribing in people with a life-limiting disease is crucial for the development of successful deprescribing interventions. These barriers/enablers have been studied, but the available evidence has not been summarized in a systematic review. AIM:: To identify the barriers/enablers to deprescribing of medications in people with a life-limiting disease. DESIGN: : Systematic review, registered in PROSPERO (CRD42017073693). DATA SOURCES:: A systematic search of MEDLINE, Embase, Web of Science and CENTRAL was conducted and extended with a hand search. Peer-reviewed, primary studies reporting on barriers/enablers to deprescribing in the context of explicit life-limiting disease were included in this review. RESULTS: : A total of 1026 references were checked. Five studies met the criteria and were included in this review. Three types of barriers/enablers were found: organizational, professional and patient (family)-related barriers/enablers. The most prominent enablers were organizational support (e.g. for standardized medication review), involvement of multidisciplinary teams in medication review and the perception of the importance of coming to a joint decision regarding deprescribing, which highlighted the need for interdisciplinary collaboration and involving the patient and his family in the decision-making process. The most important barriers were shortages in staff and the perceived difficulty or resistance of the nursing home resident's family - or the resident himself. CONCLUSION AND IMPLICATIONS OF KEY FINDINGS: : The scarcity of findings in the literature highlights the importance of filling this gap. Further research should focus on deepening the knowledge on these barriers/enablers in order to develop sustainable multifaceted deprescribing interventions in palliative care.
BACKGROUND: : Knowing the barriers/enablers to deprescribing in people with a life-limiting disease is crucial for the development of successful deprescribing interventions. These barriers/enablers have been studied, but the available evidence has not been summarized in a systematic review. AIM:: To identify the barriers/enablers to deprescribing of medications in people with a life-limiting disease. DESIGN: : Systematic review, registered in PROSPERO (CRD42017073693). DATA SOURCES:: A systematic search of MEDLINE, Embase, Web of Science and CENTRAL was conducted and extended with a hand search. Peer-reviewed, primary studies reporting on barriers/enablers to deprescribing in the context of explicit life-limiting disease were included in this review. RESULTS: : A total of 1026 references were checked. Five studies met the criteria and were included in this review. Three types of barriers/enablers were found: organizational, professional and patient (family)-related barriers/enablers. The most prominent enablers were organizational support (e.g. for standardized medication review), involvement of multidisciplinary teams in medication review and the perception of the importance of coming to a joint decision regarding deprescribing, which highlighted the need for interdisciplinary collaboration and involving the patient and his family in the decision-making process. The most important barriers were shortages in staff and the perceived difficulty or resistance of the nursing home resident's family - or the resident himself. CONCLUSION AND IMPLICATIONS OF KEY FINDINGS: : The scarcity of findings in the literature highlights the importance of filling this gap. Further research should focus on deepening the knowledge on these barriers/enablers in order to develop sustainable multifaceted deprescribing interventions in palliative care.
Entities:
Keywords:
Drug utilization; deprescriptions; palliative care; systematic review
Authors: Lucas Morin; Jonas W Wastesson; Marie-Laure Laroche; Johan Fastbom; Kristina Johnell Journal: Palliat Med Date: 2019-06-07 Impact factor: 4.762
Authors: Bregje A A Huisman; Eric C T Geijteman; Marianne K Dees; Noralie N Schonewille; Margriet Wieles; Lia van Zuylen; Karolina M Szadek; Agnes van der Heide Journal: BMC Palliat Care Date: 2020-05-13 Impact factor: 3.234
Authors: Sue Jordan; Hayley Prout; Neil Carter; John Dicomidis; Jamie Hayes; Jeffrey Round; Andrew Carson-Stevens Journal: PLoS One Date: 2021-01-07 Impact factor: 3.240
Authors: Antonio Olry de Labry Lima; Jorge Marcos Marcos; Alfonso Marquina Marquez; María de Los Ángeles González Vera; Antonio Matas Hoces; Clara Bermúdez Tamayo Journal: BMC Fam Pract Date: 2020-06-08 Impact factor: 2.497
Authors: Natacha Christina de Araújo; Erika Aparecida Silveira; Brenda Godoi Mota; João Paulo Neves Mota; Ana Elisa Bauer de Camargo Silva; Rafael Alves Guimarães; Valéria Pagotto Journal: PLoS One Date: 2020-10-28 Impact factor: 3.240
Authors: Yee Lin Chock; Yuan Lin Wee; Su Lene Gan; Kah Woon Teoh; Khuen Yen Ng; Shaun Wen Huey Lee Journal: J Gen Intern Med Date: 2021-06-25 Impact factor: 5.128